Related Experiment Video

Updated: Jun 9, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Practice-Changing Advances in Systemic Therapies Shaping the Landscape of Lung Cancer in 2025

Zhenyu Zhou1, Wanting Gao1,2, Molly S C Li3

  • 1Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences Southern Medical University Guangzhou Guangdong China.

Cancer Innovation
|June 8, 2026
PubMed

Insights

Lung cancer treatment has advanced significantly due to targeted therapies, immunotherapies, and new drug classes like antibody-drug conjugates. These innovations are improving outcomes across all stages of non-small cell lung cancer and small cell lung cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Lung cancer treatment has been revolutionized by molecular profiling and precision therapeutics.
  • Significant declines in lung cancer mortality are observed, driven by early detection and surgical advancements.
  • Systemic therapies have evolved with the integration of antibody-drug conjugates (ADCs) and bispecific antibodies (BsAbs).

Purpose of the Study:

  • To review pivotal evidence presented at key oncology forums in 2025.
  • To delineate the evolved clinical landscape of lung cancer treatment.
  • To highlight therapeutic successes across all disease stages and subtypes of lung cancer.

Main Methods:

  • Comprehensive review of pivotal evidence from major oncology forums in 2025.
  • Synthesis of data on targeted and immunotherapeutic strategies.
  • Analysis of advancements in systemic therapies including ADCs and BsAbs.

Main Results:

  • 2025 marks a period of significant progress in lung cancer treatment.
  • Groundbreaking therapeutic successes observed across all lung cancer stages and subtypes.
  • Evolved clinical landscape characterized by novel targeted and immunotherapeutic approaches.

Conclusions:

  • Targeted and immunotherapeutic strategies have fundamentally reshaped lung cancer management.
  • Continued advancements in systemic therapies are crucial for improving patient outcomes.
  • The integration of new drug modalities like ADCs and BsAbs signifies a new era in lung cancer pharmacotherapy.
Keywords:
T‐cell engagersantibody‐drug conjugatesbispecific antibodieslung cancerneoadjuvant immunotherapytargeted therapy

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...